Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In China, A Province's Drastic Price Cut Model Is Being Modified To Fit A Nationwide System: A Look At The Anhui Model

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Since China's healthcare reforms started in 2009, the central government has been encouraging local government to pilot different tender models for essential drugs to reduce public medical expenses. Anhui Province's tender system became a successful example by reducing essential drug prices an average 40-50% last year, and now the central government is implementing a single supplier procurement system, the so-called Anhui model, nationwide
Advertisement

Related Content

New Growth Models In China: McKinsey-PharmAsia Summit Report Preview
New Growth Models In China: McKinsey-PharmAsia Summit Report Preview
Will A Powerful New Ministry Lead To A Favorable Regulatory Environment In China?
China Pharma And Distributors Suffer From Essential Drug System And Price Cuts
China Pharma And Distributors Suffer From Essential Drug List System And Price Cuts
Anhui Model Suggests More Pricing Pressure From Chinese Drug Tenders
China Reviews Essential Drug Pricing Model After GMP Violations From Multi-bid Winner
China Reviews Essential Drug Pricing Model After GMP Violations From Multi-bid Winner
China Distributor Consolidation Heats Up: Sinopharm Looks To Raise $440 Million Ahead Of Shanghai Pharma IPO
China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected
Advertisement
UsernamePublicRestriction

Register

SC077854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel